Videssa
Commercial- Indications
- Breast cancer
Company intelligence / Profile preview
Provista Diagnostics developed and commercialized proprietary blood-based diagnostic tests, most notably the Videssa® breast cancer blood test. The company operated a CLIA/CAP-certified lab with capabilities for PCR, ELISA, NGS, and other advanced diagnostics. After its acquisition by Todos Medical in 2021, the lab expanded to include COVID‑19 testing (including variant analysis) and Long COVID panel analyses. The Videssa® test was positioned as an early detection tool for breast cancer. No clinical trial results or peer-reviewed data summaries were found in the provided sources.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Provista Diagnostics.